Valuation: China Biotech Services Holdings Limited

Market Cap 483M 61.59M 55M 50.81M 46.04M 86.14M 5.85B 87.57M 611M 242M 3.06B 231M 226M 9.66B P/E 2024
-2.49x
P/E 2025 -11.2x
Enterprise Value 866M 110M 98.59M 91.08M 82.54M 154M 10.48B 157M 1.1B 434M 5.49B 414M 406M 17.31B EV / Sales 2024
9.45x
EV / Sales 2025 15.7x
Free-Float
35.46%
Yield 2024 *
-
Yield 2025 -
08-28 China Biotech Services Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2026 CI
08-12 China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2026 CI
08-11 China Biotech Services Holdings Limited and Stella Pharma Corporation Enter Master Collaboration Agreement for Commercialisation of BNCT Drug CI
08-03 China Biotech Services Holdings Limited's Japan, Pengbo Medical Technology Co., Ltd. Present of Initial Follow-Up Findings of Boron Neutron Capture Therapy At the 22Nd Congress on Neutron Capture Therapy CI
05-18 China Biotech Services' unit disposes entire stake in PHC Medical Diagnostic Centre, others RE
04-30 China Biotech Services says He Xun resigns as executive director RE
04-30 China Biotech Services Holdings Limited Announces Resignation He Xun as Executive Director, Effective May 1, 2026 CI
04-28 China Biotech Services Holdings Limited Auditor Raises 'Going Concern' Doubt CI
03-27 China Biotech Services Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-06 China Biotech Services expects FY net loss of not more than HK$100 million RE
03-06 China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025 CI
02-19 China Biotech Services Holdings Limited announced that it has received HKD 272.3 million in funding from Wealth Strategy Holding Ltd CI
12-29 China Biotech Services to issue convertible bonds RE
1 day-1.00%
1 week-2.94%
Current month-18.85%
1 month-12.39%
3 months-23.85%
6 months-28.26%
Current year-37.34%
1 week 0.48
Extreme 0.48
0.54
1 month 0.48
Extreme 0.48
0.62
Current year 0.3
Extreme 0.3
0.92
1 year 0.3
Extreme 0.3
1.04
3 years 0.25
Extreme 0.25
1.33
5 years 0.25
Extreme 0.25
2.64
10 years 0.23
Extreme 0.23
2.64
Manager TitleAgeSince
Director of Finance/CFO - -
Compliance Officer 55 2022-05-25
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 60 2017-08-06
Director/Board Member 44 2017-09-14
Chairman 55 2017-08-27
Date Insider Type Main position Quantity % Market Cap. Importance
3/30/26 Other

Chairman

3,600,000 0.3690%
9/2/24 Other

Director

3,220,000 0.3300%
6/13/24 Other

Director

5,000,000 0.5191%
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-2.94%-48.44%-22.66% 61.59M
-1.07%+1.20%+15.30%+35.48% 120B
+0.37%+2.22%+6.56%+94.67% 102B
+0.64%+2.67%+107.15%+907.86% 58.23B
+1.75%+2.27%-5.86%+82.21% 29.08B
-0.57%+2.93%+32.01%+99.17% 26.7B
-0.30%+3.46%+15.83%+66.20% 26.68B
-0.81%+0.45%+29.74%+391.13% 21.62B
-2.46%-5.71%-23.17%-7.12% 19.58B
-0.68%+2.72%+4.02%+82.89% 18.93B
Average -0.41%+0.53%+13.31%+172.98% 42.19B
Weighted average by Cap. -0.25%+1.64%+23.94%+197.66%

Financials

2024 2025
Net sales 70.51M 8.99M 8.03M 7.42M 6.72M 12.58M 854M 12.78M 89.26M 35.34M 447M 33.74M 33.02M 1.41B 73.5M 9.37M 8.37M 7.73M 7.01M 13.11M 890M 13.33M 93.05M 36.84M 466M 35.17M 34.43M 1.47B
Net income -198M -25.27M -22.56M -20.84M -18.89M -35.34M -2.4B -35.92M -251M -99.31M -1.26B -94.82M -92.81M -3.96B -68.78M -8.77M -7.83M -7.24M -6.56M -12.27M -833M -12.47M -87.06M -34.47M -436M -32.91M -32.21M -1.38B
Net Debt 169M 21.54M 19.23M 17.77M 16.1M 30.13M 2.04B 30.63M 214M 84.66M 1.07B 80.84M 79.12M 3.38B 383M 48.81M 43.59M 40.27M 36.49M 68.28M 4.63B 69.41M 485M 192M 2.43B 183M 179M 7.65B
Projected Income Statement - Annual - China Biotech Services Holdings Limited
Logo China Biotech Services Holdings Limited
China Biotech Services Holdings Ltd, formerly Rui Kang Pharmaceutical Group Investments Ltd, is an investment holding company principally engaged in the provision of medical health check services. The Company operates its business through six segments. The Medical and Health Related Services segment provides medical laboratory testing services and health check services. The Insurance Brokerage segment is engaged in the provision of brokerage services. The Immunotherapy segment provides tumor immune call therapy, immune cell storage and health management services. The Pharmaceutical Products segment is engaged in the manufacture, research and development, sale and distribution of health related and pharmaceutical products. The Securities segment is engaged in the trading of securities. The Others segment is engaged in the money lending business and provision of logistic services.
Employees
166
Date Price Change Volume
26-10-23 HK$0.4950 -1.00% 250,000
26-10-22 HK$0.5000 -1.96% 275,000
26-10-21 HK$0.5100 -5.56% 90,000
26-10-20 HK$0.5400 +5.88% 220,000
26-10-16 HK$0.5100 -1.92% 10,000
  1. Stock Market
  2. Stocks
  3. 8037 Stock